> ## Content Index > Fetch the complete content index at: https://compounded.ghost.io/llms.txt > Use this file to discover other available public pages before exploring further. # The RSV Vaccine Works Well in Year One. Year Three Is the Open Question. - URL: https://compounded.ghost.io/the-rsv-vaccine-works-well-in-year-one-year-three-is-the-open-question/ - Published: 2026-10-29T10:33:00.000Z - Updated: 2026-10-29T10:32:59.000Z - Author: Connor Hayes Respiratory syncytial virus spent decades filed under childhood illness. In older adults it is a serious respiratory infection that fills hospital beds every winter, and until 2023 there was nothing to prevent it. Vaccines for adults over 60 arrived that year, and three seasons of real-world data now exist. The first-season results are strong by any standard. An analysis of more than 14.5 million Americans aged 65 and over found roughly 82 percent effectiveness against RSV hospitalization and 85 percent against RSV-related death, with protection holding in people over 85 and reaching about 72 percent in immunocompromised patients. The question that has emerged since is not whether the vaccine works. It is how long one dose keeps working. ### From the Lab to the Ledger RSV was a difficult vaccine target for a long time, and the reason is a lesson in structural biology. The virus uses a surface protein called F to fuse with the cells it infects, and that protein changes shape dramatically during the process. The pre-fusion form is the one the most powerful neutralizing antibodies recognize, and it is unstable, collapsing into the post-fusion shape that generates much weaker protection. Early vaccine attempts presented the wrong shape. The breakthrough was engineering a stabilized pre-fusion F protein that holds its original conformation. Every approved adult RSV vaccine is built on that, with one adding an adjuvant to strengthen the immune response and another delivered as mRNA instructions for the body to build the protein itself. The durability data is where the picture gets more textured. A study in adults 60 and over with a high burden of other conditions tracked one manufacturer's vaccine across three seasons. Effectiveness against RSV lower respiratory disease requiring hospital or emergency care was about 80 percent in the first season, about 70 percent in the second, and about 51 percent in the third, with a confidence interval wide enough that protection in year three could not be established. Against acute respiratory illness the third-season estimate was about 60 percent and did hold. That pattern, strong early protection declining over subsequent seasons, is the central practical fact and the one current recommendations are still catching up with. It is also not unusual. Protection from a single dose waning over several years is familiar from other vaccines, and it is the reason some are given on a repeating schedule rather than once. What is unusual here is that the schedule was set before the durability data existed, which is unavoidable when a vaccine is new and the need is immediate. ### Bio-Pipeline Ledger Adjuvanted pre-fusion F protein vaccine: approved for older adults, with first-season effectiveness around 82 percent against hospitalization in a very large real-world analysis. Validated, with the durability question shared across the class. Bivalent pre-fusion F protein vaccine: approved, with three seasons of follow-up showing clear decline by the third year. Validated for first-season protection. mRNA RSV vaccine: approved for older adults, newer to market with less real-world durability data accumulated. Available, with the long-term picture still filling in. Revaccination schedules: not settled. Whether and when a second dose should be given is an active question rather than a defined recommendation. Monoclonal antibody prevention for infants: a separate and well-validated approach for the other population RSV hits hardest, not interchangeable with adult vaccination. ### The Clinical Reality Check The case for vaccination in the eligible age group is solid. An 82 percent reduction in hospitalization, with a comparable effect on death, is a large effect for a respiratory vaccine, and it held across age bands including the oldest patients and reasonably well in people with suppressed immune systems. Those are exactly the people RSV puts in hospital. What is not resolved is the schedule. The vaccine was introduced as a single dose, and the three-season data suggests that assumption may not hold. Advisory committees have been working through this, and anyone who was vaccinated in the first season is in a position no recommendation fully covers yet. That is a reasonable thing to raise with a physician or pharmacist, particularly for someone with chronic lung disease, heart failure or immune suppression, where the stakes of waning protection are highest. Two other honest qualifications. Real-world effectiveness estimates carry wide uncertainty, especially in the later seasons where fewer events accumulate, so the decline is clearer in direction than in magnitude. And a rare risk of Guillain-Barré syndrome has been monitored in this age group since launch, which is part of why recommendations have been written and revised carefully rather than broadened quickly. The practical version is short. If you are in the recommended age group and have not had an RSV vaccine, the first-season evidence is about as good as this category gets. If you were vaccinated in 2023, the useful question is not whether it worked, but whether it still is, and that is a question to put to a clinician rather than to answer from a chart. ![](https://storage.ghost.io/c/93/20/932004ad-b501-4cef-8a02-28e1473c42cb/content/images/2026/10/rsv-vaccine-older-adults-durability-2-cinematic.jpg) ###